Search for a trial

Linking movement execution and perception in Autism Spectrum Disorder

1) Assess whether individuals with ASD perform pantomimes with similar kinematics to typical individuals, and whether the typicality of their kinematics can be explained by motor impairment.2) Assess whether individuals with ASD are able to utilize…

Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.

The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.